Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma by Rabinowits, Guilherme
Baptist Health South Florida 
Scholarly Commons @ Baptist Health South Florida 
All Publications 
6-5-2020 
Association of Programmed Death 1 Protein Ligand (PD-L1) 
Expression With Prognosis in Merkel Cell Carcinoma 
Guilherme Rabinowits 
Baptist Health Medical Group; Miami Cancer Institute, guilhermer@baptisthealth.net 
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications 
Citation 
Front Med (Lausanne) (2020) 7:198 
This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health 
South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly 
Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net. 
ORIGINAL RESEARCH
published: 05 June 2020
doi: 10.3389/fmed.2020.00198
Frontiers in Medicine | www.frontiersin.org 1 June 2020 | Volume 7 | Article 198
Edited by:
Michel Goldman,
Institute for Interdisciplinary Innovation
in Healthcare (I3h), Belgium
Reviewed by:
Xin Lai,
University Hospital Erlangen, Germany
Anca Maria Cimpean,
Victor Babes University of Medicine
and Pharmacy, Romania
Kotaro Nagase,
Saga University, Japan
*Correspondence:
Jochen H. Lorch
jochen_lorch@dfci.harvard.edu
Specialty section:
This article was submitted to
Precision Medicine,
a section of the journal
Frontiers in Medicine
Received: 27 February 2018
Accepted: 23 April 2020
Published: 05 June 2020
Citation:
Hanna GJ, Kacew AJ, Tanguturi AR,
Grote HJ, Vergara V, Brunkhorst B,
Rabinowits G, Thakuria M,
LeBoeuf NR, Ihling C, DeCaprio JA
and Lorch JH (2020) Association of
Programmed Death 1 Protein Ligand
(PD-L1) Expression With Prognosis in
Merkel Cell Carcinoma.
Front. Med. 7:198.
doi: 10.3389/fmed.2020.00198
Association of Programmed Death 1
Protein Ligand (PD-L1) Expression
With Prognosis in Merkel Cell
Carcinoma
Glenn J. Hanna 1, Alec J. Kacew 1, Anusha R. Tanguturi 2, Hans J. Grote 3, Victoria Vergara 1,
Beatrice Brunkhorst 4, Guilherme Rabinowits 5, Manisha Thakuria 6, Nicole R. LeBoeuf 6,
Christian Ihling 7, James A. DeCaprio 8 and Jochen H. Lorch 1*
1Head and Neck Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States,
2 Boston University School of Medicine, Boston, MA, United States, 3Merck KGaA, Darmstadt, Germany, 4 EMD Serono,
Research and Development Institute, Billerica, MA, United States, 5Hematology/Oncology, Miami Cancer Institute, Miami,
FL, United States, 6Dermatology, Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital,
Boston, MA, United States, 7Merck KGaA, Darmstadt, Germany, 8Molecular and Cellular Oncology, Department of Medical
Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Background:Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer. Prior to
the advent of immunotherapy, treatment options were limited. In our study, we evaluate
the impact of tumor cell PD-L1 expression and tumor immune microenvironment on
survival in MCC patients who were not treated with immune checkpoint inhibitors.
Methods: Clinical data and tissue samples were collected from 78 patients with
confirmed MCC treated at Dana-Farber Cancer Institute. Specimens were analyzed
for the distribution of PD-L1 by immunohistochemistry staining (IHC) and standardized
analysis. Results were correlated with survival data.
Results: In this study, membrane and cytoplasmic MCC tumor cell staining for PD-L1
was detected in 22.4% (15 of 67) of cases and PD-L1 staining of intratumoral
microvessels and PD-L1 positive immune cells at the infiltrative margins of the tumor
in 92.5% (62 of 67) of cases. In patients untreated with immune checkpoint inhibitors,
median overall survival was not different for patients based on PD-L1 expression (PD-L1+
64 months vs. PD-L1- not reached; HR = 1.26, 95% CI: 0.46–3.45; p = 0.60).
Conclusion: PD-L1 expression is frequently detected in MCC tumor cells and tumor
microenvironment. PD-L1 expression did not affect prognosis in this cohort that had not
received PD-1/L1 blockade.
Keywords: PD-L1, merkel cell carcinoma, cancer, neuroendocrine carcinoma, prognostic biomarkers, merkel cell
polyomavirus, MCPyV
INTRODUCTION
Merkel cell carcinoma (MCC) is a rare neuroendocrine skin neoplasm that resembles normal
Merkel cells that reside within the basal layer of the epidermis (1). MCC typically occurs in
sun-exposed areas of the head and neck and in patients with an altered immune system (2, 3).
Recently, the Merkel cell polyomavirus (MCPyV) was discovered to be associated with a majority
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of MCC cases (4). Viral genome integration into the tumor
genome precedes clonal expansion, supporting a potential
pathogenic role for this virus (5). The genomic alterations seen
in MCC overlap with small cell lung cancer, a more prevalent
neuroendocrine carcinoma, with translocations and deletions in
chromosome 1 occurring in up to 40% of cases (6).
Locally advanced MCC is typically treated with wide local
excision with or without adjuvant radiotherapy, and cure rates
are high (7). However, recurrence rates for MCC approach
60% with most recurrences occurring within 2 years of primary
treatment−52% are reported to occur in regional nodes and 34%
represent distant recurrences (8). Even in the face of locoregional
recurrence, up to 60% of patients can be salvaged with re-excision
and adjuvant radiotherapy (9). Factors associated with decreased
overall survival are age≥75, male sex, tumor size≥2 cm, positive
margins, and ≥1 positive node (10). Palliative chemotherapy is
usually not effective beyond first-line treatment.
The advent of checkpoint blockade therapy targeting
programmed cell death protein-1 (PD-1) and its ligand (PD-L1)
have altered the treatment of many cancer types. Since MCC
occurs more frequently in patients who are immunosuppressed
(e.g., solid organ transplant patients) and since tumor and
blood of patients with MCC often harbor MCPyV oncoprotein
specific T-cells, MCC is a natural candidate for therapies
targeting the immune system (11, 12). In recent years, three
landmark immune checkpoint inhibitor studies in advanced
MCC have been published. One investigated the PD-1 inhibitor
pembrolizumab (13), one the PD-1 inhibitor nivolumab (14),
and another the PD-L1 inhibitor avelumab (15). All studies
showed impressive activity and most adverse events were
low grade consisting primarily of fatigue and infusion-related
reactions. Based on the avelumab JAVELIN Merkel 200 data, the
FDA granted approval for avelumab as the first drug indicated for
this patient population (15). Immunotherapy has now become
a standard of care in this disease, having shown higher rates of
durable response than expected for cytotoxic chemotherapy.
In this study, we tested whether tumoral PD-L1 expression
had any impact on survival in MCC patients who had not
received immunotherapy. Given that each of the immunotherapy
trials did not have control arms, our data can serve as a point
of comparison for patients not treated with immunotherapy (i.e.,
as a control group for future prospective studies). It is unlikely
that a study like this will be able to be replicated in the future, as
immunotherapy is now considered standard-of-care in MCC.
METHODS
Clinical data and tissue samples were analyzed from 78 patients
with pathologically confirmed (CK-20 positive) MCC who were
to be treated at Dana-Farber Cancer Institute, diagnosed between
2002 and 2010. The clinical data collected included age, gender,
date of diagnosis, primary site of disease, clinical staging, and
survival. The tissue samples analyzed consisted of cutaneous
tumor biopsies and resected regional lymph node metastases. We
utilized IHC with a proprietary avelumab/Merck/Pfizer analytic
PD-L1 antibody clone 73-10 (a rabbit monoclonal recombinant
antibody), to characterize formaldehyde fixed paraffin embedded
(FFPE) tissue blocks from each patient. Individual patient
samples were arranged in triplicate as a tissue microarray (TMA)
to facilitate group staining.
Specimens were analyzed for the presence and distribution of
PD-L1 immunoreactivity. Semi-quantitative scoring for PD-L1
utilized the H-score. The percentage of negative (0), weakly
stained (1), moderately stained (2), and strongly stained (3)
tumor cells was estimated. Subsequently the H-score was
calculated as follows: H-score = (weak)% × 1 + (moderate)%
× 2 + (strong)% × 3, as previously described (16). An H-score
greater than zero was counted as positive PD-L1 staining.
Two independent surgical pathologists participated in verifying
the results (Ihling C and Grote HJ, Merck KGaA, Clinical
Biomarkers, and Companion Diagnostics).
Given the relatively small sample size, we used general
descriptive statistics to represent most data. Overall survival (OS)
was defined as time from study entry to death, otherwise this
was censored at date last known alive. Kaplan-Meier statistics
were applied using log-rank testing to evaluate outcome data.
A Pearson coefficient was used to evaluate for association.
All statistical testing used a significance cutoff of <0.05 and
were 2-sided.
RESULTS
Of the 78 cases in the population, the median age at diagnosis was
69 (range 45–95 years) as noted in Table 1. Thirty (38.5%) of 78
patients were female. The majority of patients presented with a
primary site of cutaneous disease on an extremity or in the head
and neck region. Twelve (15.4%) patients had stage I disease, 21
TABLE 1 | Baseline characteristics of patients with Merkel cell carcinoma.
(Range)
Median age at diagnosis 69 (45–95)
Gender (%)
Male 48 (61.5)
Female 30 (38.5)
Primary site
Upper extremity 23 (29.5)
Lower extremity 34 (47.4)
Head & neck 19 (24.4)
Torso 1 (1.3)
Genital 1 (1.3)
Staging at diagnosis*
I 12 (15.4)
II 21 (26.9)
III 41 (52.6)
IV 1 (1.3)
Mos (range) (%)
Median survival 40 (5–113)
Death at the time of analysis (%) 34 (43.5)
*Three patients’ staging information was unavailable.
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FIGURE 1 | (A) Merkel cell carcinoma case (40x) demonstrating typical morphology with tumor cells arranged in a diffuse fashion showing scant amphophilic or
eosinophilic cytoplasm and relatively uniform nuclei. The nuclei have finely dispersed chromatin without prominent nucleoli. (B) CK-20 staining pattern in patients with
Merkel cell carcinoma (cells are arranged in groups of three, with three horizontal cells representing triplicate samples from a single tumor). (C) Rabbit IgG isotype
immunohistochemistry (control). (D) PD-L1 staining in patients with Merkel cell carcinoma (cells are arranged in groups of three, with three horizontal cells representing
triplicate samples from a single tumor).
TABLE 2 | Immunohistochemical staining with anti-PD-L1 clone 73-10 in patients with Merkel cell carcinoma and intratumoral expression of PD-L1.
Subjects Tumor tissue (% cells)
cytoplasm
H-score
cytoplasm
Tumor tissue (% cells) membrane H-score
membrane
Tumor infiltrating
immune cells
(TIICs) (“+” or “-”)
Negative Weak Moderate Strong Sum (%) Negative Weak Moderate Strong Sum (%)
1 97 0 3 0 100 6 97 0 3 0 100 6 -
2 98 0 2 0 100 4 98 0 2 0 100 4 -
3 97 0 3 0 100 6 97 0 3 0 100 6 -
4 98 0 2 0 100 4 98 0 2 0 100 4 +
5 99 0 1 0 100 2 99 0 1 0 100 2 +
6* 98 0 2 0 100 4 98 0 2 0 100 4 +
7 99 0 1 0 100 2 99 0 1 0 100 2 +
8* 99 1 0 0 100 1 99 1 0 0 100 1 -
9∧ 99 0 1 0 100 2 99 0 1 0 100 2 +
10* 99 0 1 0 100 2 99 0 1 0 100 2 +
11 97 0 3 0 100 6 97 0 3 0 100 6 +
12 99 0 1 0 100 2 99 0 1 0 100 2 +
13 100 0 0 0 100 0 99 1 0 0 100 1 -
14 99 0 1 0 100 2 99 0 1 0 100 2 +
15 99 0 1 0 100 2 99 0 1 0 100 2 +
*Intratumoral microvessels staining for PD-L1.
∧Nuclear staining of tumor cells for PD-L1.
Semi-quantitative scoring for PD-L1 utilized the H-score. The percentage of negative (0), weakly stained (1), moderately stained (2) and strongly stained (3) tumor cells was estimated.
Subsequently the H-score was calculated as follows: H-score= (weak)%× 1+ (moderate)%× 2+ (strong)%× 3. An H-score greater than zero was counted as positive PD-L1 staining.
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FIGURE 2 | (A) PD-L1 staining of a Merkel cell carcinoma (case 12-5684, 40x)
showing tumor cells with membrane associated as well as cytoplasmic PD-L1
staining. (B) A Merkel cell carcinoma sample with prominent PD-L1 staining of
intra-tumoral microvessels (40x). (C) Tumor cells lacking PD-L1 expression. By
contrast, within the tumor there are scattered PD-L1 positive immune cells
with weak membrane and cytoplasmic PD-L1 staining.
(26.9%) had stage II, 41 (52.6%) had stage III, and one (1.3%)
had stage IV disease. The initial staging information for three
patients was unavailable. Median survival time was 40 (range: 5–
113) months. Thirty-four patients (43.5%) had died at the point
of analysis.
Tumor samples confirmed as MCC were composed of
trabecular to insular or diffuse proliferations of tumor
cells with scant amphophilic or eosinophilic cytoplasm and
relatively uniform nuclei sometimes exhibiting nuclear molding
(Figure 1A). Additionally, CK-20 immunohistochemical
TABLE 3 | Median survival depending on the PD-L1 expression and stage of
disease.
PD-L1+
expression
PD-L1-
expression
Hazards
ratio
95% CI P-value
OS in PD-L1
expression
months
64.0 months NR 1.26* 0.46–3.46 0.601
Stages of the
MCC disease
OS Between
Stage 1 and 2
OS between
Stage 3 and 4
0.99* 0.41–2.39 0.986
Expressed in
months
69.0 NR
NR, not reached; *HR changes with the change in the follow up time period; OS,
Overall survival.
staining was performed to exclude skin metastasis of small cell
lung cancer (Figure 1B). Rabbit isotypes were stained for PD-L1
to serve as controls (Figure 1C). A total of 67 out of 78 cases were
evaluable following immunohistochemical staining (cases were
excluded if tissue washed off or < 50 tumor cells were present).
PD-L1 staining in the tumor cells and in the surrounding
tumor infiltrating immune cells is shown in Figure 1D. Semi-
quantitative scoring for tumor cell PD-L1 using the H-score is
shown in Table 2. 15 of 67 (22.4%) patient tumor samples were
characterized as PD-L1 positive, with an H-score maximum of 6
for individual cases (range 1–6).
In 14 patients (20.9%), the tumor cells showed both
membrane-associated staining and cytoplasmic staining for PD-
L1 (Figure 2A). In several cases, prominent PD-L1 staining
of intratumoral microvessels was present (Figure 2B). Immune
infiltrates with PD-L1 positive cells of varying size and density
were present at the infiltrative margin of the tumor in 62
(92.5%) of 67 cases. By contrast, within the tumor specimens
we observed scattered PD-L1 positive immune cells but no
widespread or dense immune infiltrates (Figure 2C). Neither
membrane-associated nor cytoplasmic staining for PD-L1 by H-
score was correlated with the presence of infiltrating immune
cells (p-value= 0.17). Median overall survival was similar among
subgroups regardless of PD-L1 expression intensity (HR 1.26,
95% CI: 0.46–3.45, p = 0.60) (Table 3, Figure 3) and regardless
of disease site (Table 4).
DISCUSSION
MCC represents an aggressive neuroendocrine carcinoma of
the skin that is characterized by high rates of locoregional
recurrence and distant metastatic disease. While overall response
rates of advanced disease to chemotherapy regimens are
favorable, they are often of limited duration (17). The purpose
of this study was to characterize tumoral PD-L1 expression
patterns observed in MCC tumors and to determine if
these expression patterns relate to outcomes in patients not
treated with immunotherapy. Notably, three landmark studies
have recently demonstrated high response rates of MCC to
checkpoint blockade therapy targeting PD-1 and PD-L1 in MCC.
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FIGURE 3 | (A) Overall survival (all evaluable patients) (B) Overall survival by PD-L1 expression (C) Overall survival by anatomic site.
Understanding why MCC is so sensitive to PD-1 and PD-L1
targeted therapy may bring insights to guide therapy in other
tumor types.
In this study, membranous and/or cytoplasmic MCC tumor
cell staining for PD-L1 was detected in 22.4% of patients. We
found prominent PD-L1 staining associated with intratumoral
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TABLE 4 | Median survival depending on site of disease.
Median OS
in months
95% CI P-value (vs.
rest of cohort)
Upper extremity NR 44-NR 0.43
Lower extremity 131 27-NR 0.29
Head & neck 69 38-NR 0.93
Other 5 5-NR 1.00
CI, confidence interval; NR, not reached; OS, overall survival.
microvessels, which raises the possibility that these structures
may play a role in the immunologic defense of the tumor. In
addition, we noted PD-L1 positive immune cells at the infiltrative
margins of the tumor in 92.5% of cases. PD-L1 expression in the
membrane and cytoplasm of tumor cells did not affect prognosis
in this cohort that had not received immunotherapy agents.
Given the relatively large sample size in an untreated population
of MCC, this data may remain an important point of reference as
a control group for future prospective studies.
PD-L1 expression has been previously described on immune-
infiltrating cells rather than on the surface of tumor cells and
was frequently overexpressed in peripheral tumor-infiltrating
lymphocytes (TILs). Similar observations have been noted in
melanoma, in which PD-L1 positive tumor cells are often
localized near TILs (18).
Afanasiev and colleagues determined the presence of PD-
L1 within MCC tumors and characterized CD8 mRNA
expression to detect CD8+ lymphocytic infiltration (19). Biopsy
specimens from 69% of patients (9 of 13) were at least
weakly positive for PD-L1 by immunohistochemistry. They
demonstrated that high levels of PD-L1 tumoral staining
correlated with CD8 lymphocytic infiltration (p < 0.05)—
suggesting a high likelihood of inhibitory ligand matching
in the tumor microenvironment. Dowlatshahi and colleagues
similarly demonstrated that 50% of MCC T-cells expressed PD-
1 within the tumoral microenvironment (20). However, they
characterized CD69 and CD25 expression patterns on the surface
of tumor-specific T-cells, which are markers of activation. They
found severely decreased levels of these markers, suggesting
suppression of T-cell activation within the MCC tumor
microenvironment—likely reflecting T-cell exhaustion (21).
The presence of MCPyV-specific T-cells correlates with MCC
disease burden—such that MCPyV-specific T-cell increased
with growing tumor burden and coexpression of immune
checkpoint receptors, namely PD-1, was high within the MCC
tumor microenvironment (19). PD-1 was expressed in 71% of
MCC tumor-infiltrating lymphocytes and 96% of circulating
MCyV-specific T-cells. The inhibitory receptor Tim-3 was
also coexpressed more commonly in these cell types. CTLA-4
expression was generally low. However, studies assessing PD-1
and PD-L1 expression by IHC were complicated by differences in
staining properties between antibodies and a lack of standardized
criteria for analysis.
Across tumors, including those that have been studied in
much larger patient populations compared with MCC, the
proposed prognostic value of PD-L1 varies widely. Data in
breast cancer suggests that PD-L1 overexpression is associated
with lower OS (22), while data in non-small cell lung cancer
suggests PD-L1 is not a robust prognostic marker (23). PD-L1
expression is associated with longer disease-free survival in head
and neck cutaneous squamous cell carcinomas (24). Indeed, our
conclusion that PD-L1 is not an independent prognostic marker
in MCC is at odds with an earlier, smaller study in MCC, which
suggested that PD-L1 expression was associated with higher
OS (25).
Recent work suggests that PD-L1 may serve as prognostic
marker when considered in multivariate analysis with other
immune-related markers. In non-small cell lung cancer, patients
with both high PD-L1 expression and high CD8+ TIL density
experienced particularly long OS, while patients with high PD-L1
expression and low CD8+ TIL density experienced particularly
low OS (26). Further study in MCC may show that analysis
involving multiple immune components at once may hold
prognostic value for patients.
There are several lines of evidence that suggest that MCC
is particularly dependent on immune evasion. For example,
the identification of MCPyV has led to several epidemiologic
studies that demonstrate that the virus is widely prevalent and
viral capsid proteins are readily recognized by the immune
system (27). It has further been demonstrated that MCC tumor
cells express the Large T (LT) and Small T (ST) antigens;
a MCPyV protein constitutively expressed by virally infected
tumor cells (28). Antibodies to ST serve a useful biomarker
for following disease status in patients with virus-positive
MCC (29).
A phase 2 study with 26 MCC patients with with stage IIIb
and IV disease received pembrolizumab as first-line treatment
observed an overall response rate (ORR) of 56%. In this study,
neither PD-L1 expression on tumor cells nor expression on
infiltrating immune cells correlated significantly with clinical
response. Virus-positive tumors were three times more likely
to express PD-L1 compared with virus-negative tumors (71
vs. 25%, p = 0.049). Intratumoral CD8 T-cell infiltration did
not correlate significantly with clinical response or with viral
status (13).
The PD-L1 inhibitor avelumab was tested in a phase 2
study which included 88 patients with stage IV chemotherapy-
refractory, histologically confirmed metastatic MCC. The initial
report from this study led to FDA approval in MCC in 2016. In a
1-year update with median follow-up at 16.4 months and analysis
ongoing, an ORR of 33.0% was observed. In 29 patients who
had a response, 10 patients had complete response. The median
duration of response had not been reached (range 2.8–23.3+
months) (30). Amongst 58 patients who were positive for PD-L1
in the original publication, objective response was achieved in 20
(34.5%). In the recent update, post-hoc subgroup analyses were
reported. The objective response rate among those who were
PD-L1 positive remained stable at 34.5%. Six-month duration of
response (DOR) was estimated at 100% and 6-month PFS rate at
43%, thus suggesting responses had occurred later in treatment.
In our analysis, which included only patients prior to the advent
of immunotherapy treatment, there was no difference in overall
survival regardless of PD-L1 positivity (p= 0.60).
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